Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
5
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,741.90 | 26.70 | -0.30% |
| CAC 40 | 7,791.47 | 13.40 | -0.17% |
| DAX 40 | 24,174.32 | 130.14 | -0.54% |
| Dow JONES (US) | 42,761.76 | 1.11 | -0.00% |
| FTSE 100 | 8,832.28 | 5.63 | -0.06% |
| HKSE | 24,181.43 | 388.89 | 1.63% |
| NASDAQ | 19,591.24 | 61.28 | 0.31% |
| Nikkei 225 | 38,088.57 | 346.96 | 0.92% |
| NZX 50 Index | 12,539.26 | 24.22 | -0.19% |
| S&P 500 | 6,005.88 | 5.52 | 0.09% |
| S&P/ASX 200 | 8,515.70 | 23.20 | -0.27% |
| SSE Composite Index | 3,399.77 | 14.41 | 0.43% |